SeraCare Life Sciences Seraseq Solid Tumor Mutation Mix

SeraCare Life Sciences' precision medicine unit has launched its first product, Seraseq Solid Tumor Mutation Mix – I(AF20), a biosynthetic reference material designed to evaluate the performance of next-generation sequencing-based tumor profiling assays. The research-use-only product contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality material for translational and disease research testing, SeraCare said. It also allows laboratories to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics parameters.